DOI: https://dx.doi.org/10.18203/2394-6040.ijcmph20221249
Published: 2022-04-27

Call based enquiry for COVID-19 vaccine (Covishield) adverse events in a tertiary care government hospital in India

Adity Priya, Pratibha Gupta, Vijay Kumar, Salil Kumar Srivastava, Yogesh Kumar Yadav, Arshita Srivastava

Abstract


Background: Vaccination is one of the crucial intervention to fight against the ongoing COVID-19 pandemic. The ongoing vaccination drive aims for achieving national vaccination coverage. Due to the expedited roll out of COVID-19 vaccine, there has been a fear and concern regarding its safety. The present study aims to enquire actively about the adverse events after COVID-19 vaccination and disseminate this information to the public to promote vaccine acceptance.

Methods: A call based active enquiry was done to know the frequency and severity of various adverse events among the recipients of COVID-19 vaccine’s Covishield (SII-ChAdOx1 nCoV-19) first dose. Call based enquiry was done for local as well as systemic adverse events on day 1, 3 and 7 of vaccination.

Results: Out of the total of 1201 who responded to calls on all three days, 766 (63.7%) of them had at least one of the adverse event. There were only 4 (0.33) recipients who had severe/serious events. The most frequent systemic and local AEFI reported was body ache/ malaise and pain at injection site in 309 (25.7%) and 664 (55.3%) participants respectively. Most of the AEFI’s improved over a week with only 17 (1.4%) participants reporting persistence of any adverse event on day 7 of vaccination.

Conclusion: Our study can provide scoping base for development of a proper surveillance program to monitor the AEFI by ‘active’ query and use of a call-based system especially for novel vaccines.


Keywords


Coronavirus disease 2019, Vaccine (Covishield), Adverse event, Telehealth

Full Text:

PDF

References


Chandna VB, Patil SM, Shirahatti PS, Sujay S, Tejaswini M, Ranganatha LV et al. The current status and perspectives for the emerging pandemic: COVID-19. Int J Pharm Pharm Sci. 2020;12:1-10.

World Health Organization. WHO coronavirus (COVID-19) dashboard. 2021. Available at: https://covid19.who.int. Accessed on June 29, 2021.

World Health Organization. AEFI training module 3. Accessed from https://www.who.int/vaccine_safety. Accessed on June 29, 2021.

Revised AEFI guidelines. Govt of India. Ministry of health and family welfare. Accessed from https://main.mohfw.gov.in/. Accessed on June 29, 2021.

Jeon M, Kim J, Oh CE, Lee JY. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System. J Korean Med Sci. 2021;36(17):e114.

Voysey M, Clemens SAC, Madhi SA. Safety and efficacy of the ChAdOx1nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99-111.